

Study Title

An open label trial of TMC114/RTV in HIV-1 infected, treatment experienced subjects.

Status

Enrolment complete

Primary Investigator at TGH

Dr. Sharon Walmsley

Sponsor

Tibotec Pharmaceuticals

Brief Description of the Study

This is an open label trial in HIV-1 infected subjects who failed trial treatment in the control group of the TMC114 dose finding trial, and who in the opinion of the investigator may derive benefit from the TMC114 therapy. In addition this trial also evaluates the safety, tolerability and efficacy of TMC114/RTV. Antiviral activity will also be evaluated.

Additional patients, who were not participating in the original dose finding trial, were recruited to further evaluate the safety and efficacy of the recommended dose of TMC114/RTV.

Study Arm

- TMC114/RTV plus the investigator selected optimized background regimen

Contact

For more information contact Adriana D'Aquila, RN @ 416-340-4800 ext: 8170,

Email: adri.d'aquila@uhn.on.ca